Statin therapy is associated with a significant reduction in hepatic decompensation risk in patients with primary biliary cholangitis (PBC).
A target trial emulation (TTE) study across two distinct populations confirms this protective association, consistent across cirrhotic and non-cirrhotic patients.
Statin use also lowers the incidence of major adverse liver outcomes (MALO), including hepatocellular carcinoma and liver transplantation.
The findings support a potential role for statins as adjunct therapy in the clinical management of PBC to prevent liver-related complications.
